Exception to payment clause applies in settlement agreement for valacyclovir
The case surrounds an agreement made following a 2009 dispute over GSK’s product Valtrex (valacyclovir hydrochloride). In 2008, Health Canada approved Pharmascience...Read More
Foolish Consistency is the Hobgoblin of Little Minds
Is an adjuvant an excipient or an active ingredient? This was the central question in the Federal Court’s decision in GSK’s application...Read More
GSK and Genentech settle Cabilly patent lawsuit
GlaxoSmithKline and Genentech have settled a U.S. lawsuit related to Genentech’s Cabilly II (US 6,331,415) and Cabilly III (US 7,923,221) patents. In...Read More